Cellulose acetate phthalate (CAP): An 'inactive' pharmaceutical excipient with antiviral activity in the mouse model of genital herpesvirus infection

Antiviral Chemistry and Chemotherapy

Volumn 10, Issue 6, 1999, Pages 327-332

  Gyotoku, T ^a   Aurelian, L ^a   Neurath, A R ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b Lindsley F Kimball Res Institute   (United States)

Author keywords

Antiviral activity; CAP; HSV 2; Microbicides; Prophylactic therapy; STD

Indexed keywords

CELLACEFATE; EXCIPIENT; GLYCEROL; SILICON DIOXIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; COMPLEX FORMATION; DRUG FORMULATION; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS INACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

EID: 0032759345     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632029901000604     Document Type: Article

References (33)

1. Arvin AM & Prober CG (1997) Herpes simplex virus type 2 - a persistent problem, New England Journal of Medicine 337:1158-1159.
2. Aurelian L (1990) Herpesviruses, the Immune System and AIDS. Boston: Kluwer Academic Publishers.
3. Aurelian L (1992) Herpes simplex viruses. In Clinical Virology Manual, 2nd Edition, pp. 473-494. Edited by S Specter & G Lancz. Amsterdam: Elsevier Science.
4. Aurelian L (1995) Transformation and mutagenic effects induced by herpes simplex virus types 1 and 2. In DNA Tumor Viruses: Oncogenic Mechanisms, pp. 253-280. Edited by G Barbanti-Brodano, M Bendinelli & H Friedman. New York: Plenum Publishing.
5. Aurelian L & Kessler II (1985) Subclinical herpes virus infections of the genital tract are commonly associated with viral shedding. Cervix 3:235-248.
6. Baba M, Snoeck R, Pauwels R & De Clercq E (1988) Sulfated polysaccharides are potent selective inhibitors of various viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus and human immunodeficiency virus. Antimicrobial Agents and Chemotherapy 32:1742-1745.
7. Beasley K, Cooley EG, Kao GF, Lowitt MH, Burnett JW & Aurelian L (1997) Herpes simplex vegetans: atypical genital herpes infection in a patient with common variable immunodeficiency Journal of the American Academy of Dermatology 37:860-863.
8. Buhler V (1996) Kollidon. Polyvinylpyrrolidone for the pharmaceutical industry. Ludwigshafen: BASF Aktiengesellschaft.
9. Di Luca D, Caselli E & Cassai E (1995) Herpes simplex virus as a cooperating agent in human genital carcinogenesis. In DNA Tumor Viruses: Oncogenic Mechanisms, pp. 281-293. Edited by G Barbanti-Brodano, M Bendinelli & H Friedman. New York: Plenum Publishing.
10. Ejercito PM, Kieff ED & Roizman B (1968) Characterization of herpes simplex virus strains differing in their effect on social behaviour of infected cells. Journal of General Virology 2:357-364.
11. Feng CP, Kulka C, Smith CC & Aurelian L (1996) Herpes simplex virus-mediated activation of human immunodeficiency virus is inhibited by oligonucleotide methylphosphonates that target immediate early mRNAs 1 and 3. Antisense Research and Nucleic Acid Drug Development 6:25-35.
12. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK & St Louis ME (1997) Herpes simplex virus type 2 in the United States, 1976 to 1994. New England Journal of Medicine 337:1105-1111.
13. Iliopoulos I, Audebert R & Quivoron C (1987) Reversible polymer complexes stabilized through hydrogen bonds. In ACS Symposium Series 350. Reversible Polymeric Gels and Related Systems, pp. 72-86. Edited by Russo PS. Washington DC: Americal Chemical Society.
14. Jennings R & Clegg A (1993) The inhibitory effect of spermicidal agents on replication of HSV 2 and HIV-1 in vitro. Journal of Antimicrobial Chemotherapy 32:71-82.
15. Kilmarx PH, Limpakarnjanarat K, Supawitkul S, Korattana S, Young NL, Parekh BS, Respess RA, Mastro TD & St Louis ME (1998) Mucosal disruption due to use of a widely-distributed commercial vaginal product: potential to facilitate HIV transmission. AIDS 12:767-773.
16. Kokuba H, Aurelian L & Neurath AR (1998) 3-Hydroxyphthaloyl β-lactoglobulin: IV. Antiviral activity in the mouse model of genital herpesvirus infection. Antiviral Chemistry & Chemotherapy 9:353-357.
17. Leiva A, Gargallo L & Radic D (1994) Interpolymer complexes. Properties and characterization. Polymer International 34:393-396.
18. Lyons JM & Ito Jr JI (1995) Reducing the risk of Chlamydia trachomatis genital tract infection by evaluating the prophylactic potential of vaginally applied chemicals. Clinical Infectious Diseases 21 (Suppl. 2):S174-S177.
19. Mertz GJ (1993) Epidemiology of genital infections. Infectious Disease Clinics of North America 7:825-839.
20. Nahmias AJ, Lee FK & Beckman-Nahmias S (1990) Sero-epidemiological and sociological patterns of herpes simplex virus infection in the world. Scandinavian Journal of Infectious Diseases 69 (Suppl.):19-36.
21. Neurath AR, Strick N, Li Y-Y, Lin K & Jiang S (1999) Design of a 'microbicide' for prevention of sexually transmitted diseases using 'inactive' pharmaceutical excipients. Biologicals 27:11-21.
22. Neurath AR, Strick N & Li Y-Y (1998) 3-Hydroxyphthaloyl β-lactoglobulin: III. Antiviral activity against herpesviruses Antiviral Chemistry & Chemotherapy 9:123-133.
23. Plaizier-Vercammen JA & De Neve RE (1980) Interaction of povidone with aromatic compounds. I: Evaluation of complex formation by factorial analysis. Journal of Pharmaceutical Sciences 69:1403-1408.
24. Posavad CM, Koelle DM, Shaughnessy MF & Corey L (1997) Severe genital herpes infections in HIV-infected individuals with impaired herpes simplex virus-specific CD8+ cytotoxic T lymphocyte responses. Proceedings of the National Academy of Sciences, USA 94:10289-10294.
25. Richards JT, Kern ER, Overall JC & Glasgow LA (1981) Differences in neurovirulence among isolates of herpes simplex virus types 1 and 2 in mice using four routes of infection. Journal of Infectious Diseases 144:464-471.
26. Smee DF, Martin JC, Verheyden JPH & Matthews TR (1983) Antiherpesvirus activity of the acyclic nucleoside 9-(1,3-dihydroxy-2-propoxymethyl)guanine. Antimicrobial Agents and Chemotherapy 23:676-682.
27. Stafford MK, Ward H, Flanagan A, Rosenstein IJ, Taylor-Robinson D, Smith JR, Weber J & Kitchen VS (1998) Safety study of nonoxnol-9 as a vaginal microbicide: evidence of adverse effects. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 17:1386-1390.
28. Tong P & Mutasim DF (1996) Herpes simplex virus infection masquerading as condyloma acuminata in a patient with HIV disease British Journal of Dermatology 134:797-800.
29. Wade A & Weller PJ (1994) Handbook of Pharmaceutical Excipients, 2nd Edition. Washington: American Pharmaceutical Association.
30. Walz MA, Price RW, Hayashi K, Katz BJ & Notkins AL (1977) Effect of immunization on acute and latent infections of vagino-uterine tissue with herpes simplex virus types 1 and 2. Journal of Infectious Diseases 135:744-752.
31. Whaley KJ, Barratt RA, Zeitlin L, Hoen TE & Cone RA (1993) Nonoxynol-9 protects mice against vaginal transmission of genital herpes infections. Journal of Infectious Diseases 168:1009-1111.
32. White PJ & Garnett GP (1999) Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. Sexually Transmitted Infections 75:49-54.
33. Zeitlin H, Whaley K, Hegarty TA, Moench TR & Cone RA (1997) Tests of vaginal microbicides in the mouse genital herpes model. Contraception 56:329-335.